Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study

Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study With Long Term Data Collection for the Accolade® II Hip Stem

The purpose of this study is to evaluate the success rate of cementless primary hip replacement with the Restoration® ADM X3® Acetabular System as compared to other primary hip systems in the literature, through absence of femoral head dislocation at 10 years postoperative.

Study Overview

• Status: Active, not recruiting
• Conditions: Arthroplasty, Replacement, Hip
• Intervention / Treatment: Device: Restoration ADM X3 Device

Detailed Description

This study is a prospective, open-label, post-market, non-randomized, multi-center, clinical evaluation of the Restoration® ADM X3® Acetabular System for primary total hip arthroplasty (THA) with a cementless application in a consecutive series of patients who meet the eligibility criteria. The total enrollment goal for the study is 350 cases, all of which will receive the Restoration® ADM X3® Acetabular System. A minimum of 100 cases (within the study population) will receive the Accolade® II Hip Stem. The remaining cases will receive any other compatible Stryker femoral component.

Data in the literature from other primary hip systems and similar dual mobility cups will be used as historical references.

• Study Type: Interventional
• Enrollment (Actual): 352
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1H8L6
      • The Ottawa Hospital
    • Toronto, Ontario, Canada, M5B 1W8
      • St. Michael's Hospital
• Germany
  • Sachsen-Anhalt
    • Magdeburg, Sachsen-Anhalt, Germany, 39120
      • Universitatsklinikum Madgeburg A.o.R. Orthopadische Universitatsklinikum Haus 8
• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • OrthoArizona
    • Phoenix, Arizona, United States, 85016
      • Arizona Institute for Bone and Joint Disorders
    • Tucson, Arizona, United States, 85712
      • Tucson Orthopaedic Institute
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
  • Michigan
    • Saginaw, Michigan, United States, 48602
      • Covenant Medical Center
  • Minnesota
    • Sartell, Minnesota, United States, 56377
      • St. Cloud Orthopedic Associates
  • Missouri
    • Columbia, Missouri, United States, 65212
      • Missouri Orthopaedic Institute
  • New York
    • Fayetteville, New York, United States, 13066
      • Syracuse Orthopedic Specialists
    • New York, New York, United States, 10021
      • Hospital for Special Surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient has signed an IRB/EC approved, study specific Informed Patient Consent Form.
• Patient is a male or non-pregnant female, skeletally mature and age 18-75 years at time of study device implantation.
• Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).
• Patient is a candidate for a primary cementless acetabular replacement.
• Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.

Exclusion Criteria:

• Patient has a Body Mass Index (BMI) ≥ 40.
• Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.
• Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device.
• Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration.
• Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days).
• Patient requires revision surgery of a previously implanted total hip replacement or hip fusion to the affected joint.
• Patient has a known sensitivity to device materials.
• Patient is a prisoner.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Restoration ADM X3 Device; Restoration ADM X3 Device in total hip replacement.	Device: Restoration ADM X3 Device; Restoration ADM X3 Device in total hip replacement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Success Rate	Defined as absence of postoperative femoral head dislocation.	10 years postoperative

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Harris Hip Score (HHS) score improvement from preoperative score	The Harris Hip Score (HHS) assesses pain, function, joint deformity and range of motion. Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor. 90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor	pre-op, 6 week, 1,2,3,4,5 years
All Cause Revision and Removal Rates of the Restoration ADM X3 Acetabular System		10 years
Patient Satisfaction and Pain: Follow-up Questionnaire	This questionnaire will be used to obtain the following information: Satisfaction with the hip replacement; Presence of any pain in the study hip; Surgeries performed on the study hip; Any dislocations in the study hip	6-10 years
Radiographic Stability Rates	Cases that present with migration of greater than 5 mm in any direction or at least 2 mm radiolucency in all zones will be considered radiographic failures.	6 week,1,2,3,4,5
Complication rates for Psoas Impingement and Associated Groin Pain		10 years
Short Form-12 (SF-12) improvement from preoperative score	The SF-12 Health Survey is a 12-item patient completed questionnaire to measure general health and well-being. It includes a physical and mental status component score; each ranging from 0-100. Low values represent a poor health state and high values represent a good health state.	preop, 6 week, 1,2,3,4,5 years
Lower Extremity Activity Scale (LEAS) improvement from preoperative score	The LEAS is completed by the participant to assess activity level. Activity levels were ordered in terms of intensity from 1 to 18, with 18 indicating the highest activity level.	preop, 6 week, 1,2,3,4,5 years
EQ-5D Index Score improvement from preoperative score	The EQ-5D is a subject-completed questionnaire designed to assess subject health state values. The EQ-5D consists of 2 areas; the EQ visual analogue scale (EQ VAS) and EQ-5D descriptive system. The EQ VAS collects health state values using a 20 cm visual analogue scale with the endpoints labeled best imaginable health state at the top and worst imaginable health state at the bottom, having numeric values of 100 to 0 respectively. The EQ-5D Time Trade-off (TTO) descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/comfort and anxiety/depression. Each dimension has three levels: no problems, some problems and extreme problems, where an overall score of 1 represents full health.	preop, 6 week, 1,2,3,4,5 years
Percentage of cases which did not have any component revised		10 years

Collaborators and Investigators

• Sponsor: Stryker Orthopaedics
• Investigators: Principal Investigator: Brett Greenky, MD, Syracuse Orthopedic Specialists; Principal Investigator: Edward Petrow, DO, Tucson Orthopaedic Institute; Principal Investigator: Anthony Hedley, M.D., Arizona Institute for Bone & Joint Disorders; Principal Investigator: Kipling Sharpe, M.D., OrthoArizona; Principal Investigator: Craig J. Della Valle, M.D., Rush University Medical Center; Principal Investigator: Geoffrey Westrich, M.D., Hospital for Special Surgery, New York; Principal Investigator: Joseph Nessler, M.D., St. Cloud Orthopedic Associates; Principal Investigator: Brian C de Beaubien, M.D., Covenant Medical Center; Principal Investigator: Christoph Lohmann, MD, Universitatsklinikum Madgeburg A.o.R.; Principal Investigator: Paul Kim, MD, The Ottawa Hospital; Principal Investigator: Ajay Aggarwal, MD, Missouri Orthopaedic Institute

Study record dates

Study Major Dates

• Study Start: June 1, 2011
• Primary Completion (Anticipated): June 1, 2026
• Study Completion (Anticipated): June 1, 2026

Study Registration Dates

• First Submitted: March 18, 2011
• First Submitted That Met QC Criteria: August 17, 2011
• First Posted (Estimate): August 19, 2011

Study Record Updates

• Last Update Posted (Actual): August 29, 2022
• Last Update Submitted That Met QC Criteria: August 26, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Noninflammatory joint disease of the hip.
• Other Study ID Numbers: 70